Metastatic breast cancer ( HER2 negative)
Clinical trials for Metastatic breast cancer ( HER2 negative) explained in plain language.
Never miss a new study
Get alerted when new Metastatic breast cancer ( HER2 negative) trials appear
Sign up with your email to follow new studies for Metastatic breast cancer ( HER2 negative), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for Hard-to-Treat breast cancer: drug duo targets rare mutation
Disease control Recruiting nowThis study tests a combination of two drugs, tucatinib and trastuzumab, in people with a specific type of advanced breast cancer that has a mutation in the HER3 gene. The cancer must be HER2-negative and has already been treated with at least two prior chemotherapies. The goal is…
Matched conditions: METASTATIC BREAST CANCER ( HER2 NEGATIVE)
Phase 2 • Sponsor: Institut Curie • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Blood test may help personalize breast cancer therapy
Disease control Recruiting nowThis study tests whether a blood test that tracks tumor DNA (ctDNA) can help doctors decide when to intensify treatment for HER2-negative metastatic breast cancer. All 122 participants start with antibody-drug conjugate (ADC) therapy. After two cycles, those whose disease hasn't …
Matched conditions: METASTATIC BREAST CANCER ( HER2 NEGATIVE)
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New scan may help match breast cancer patients to the right drug
Diagnosis Recruiting nowThis study is testing whether a new type of PET scan (TROP2-PET) can predict how well certain targeted drugs work in people with advanced HER2-negative breast cancer. The drugs, called antibody-drug conjugates, deliver chemotherapy directly to cancer cells. The study will enroll …
Matched conditions: METASTATIC BREAST CANCER ( HER2 NEGATIVE)
Phase 2 • Sponsor: Fudan University • Aim: Diagnosis
Last updated Jun 27, 2026 11:00 UTC